Press Releases/IR - Page 1 | TalkMarkets


All Posts > Content under Press Releases/IR
1 to 16 of 760 Posts
1 2 3 ... 48
Inhibikase Therapeutics: A Novel And Promising Approach To Neurodegeneration And Oncology
Article By: Bio Deep Dives
Wednesday, May 24, 2023 9:55 AM EDT
IKT's heavily discounted valuation provides a compelling risk/reward given the ability to establish both safety and efficacy in Parkinson’s disease let alone any progress in oncology.
In this article: IKT
Looking To Invest In Artificial Intelligence? Consider Evogene And Its Five Subsidiaries
Article By: Alan Sumler
Thursday, April 27, 2023 9:33 AM EDT
Evogene employs an AI platform for decoding plant phenotypes and microbial genomes. The set-up may present a long-tern investment strategy.
In this article: EVGN Also: CTVA, BAYRY, DNA, SDGR, RLAY
Biomica Announces Closing Of $20 Million Financing Round Led By Shanghai Healthcare Capital
Article By: TalkMarkets Newswire
Thursday, April 27, 2023 8:00 AM EDT
Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), today announced that it has closed a financing round of $20 million
In this article: EVGN
CoT Report: What They're Buying, What It Means
Article By: Paban Pandey
Sunday, April 9, 2023 12:03 AM EDT
Several OPEC+ members’ planned cuts in crude output may well have thrown the inflation-focused Fed a curve ball. When it is all said and done, markets in all probability are misreading the Fed’s resolve to bring inflation under control.
In this article: FXE, GLD, IVV, IWM, OIL, SPY, TLT, UUP, VOO, NDX, VIX Also: DBO, IEF, UDN
Commodities Rock As Banks Look Out Below
Video By: TheoTrade
Monday, April 3, 2023 5:23 PM EDT
OPEC news over the weekend caused oil to soar into backwardation today on significant option activity.
In this video: KGC, MRO, OXY, XOM, AGI, OIL, SLV, USO, XLE, XOP, SPY
Near Intelligence Announces Fourth Quarter And Full Year 2022 Financial Results
Article By: Business Wire
Tuesday, March 28, 2023 7:16 AM EDT
Near’s fourth quarter performance provided a solid finish to the year which was highlighted by 32% annual revenue growth and 120% net revenue retention.
In this article: NIR
Evogene Offers An Excellent Risk/Reward Ratio
Article By: Shareholders Unite
Wednesday, March 22, 2023 9:35 AM EDT
We think the company’s main CPB computational engine has the potential to be an extraordinary value creation engine.
In this article: EVGN Also: SDGR, EXAI, RLAY, DNA, CTVA, BAYRY
RenovoRx’s Principal Investigator Of Phase III Clinical Trial Discusses Positive Interim Results On Patients With Locally Advanced Pancreatic Cancer On OncologyTube
Video By: TalkMarkets Newswire
Tuesday, March 21, 2023 11:26 AM EDT
In the interview, Dr. Michael Pishvaian discussed the trial's potential impact on the oncology community as well as how pancreatic cancer patients are treated.
In this video: RNXT
RenovoRx Phase III Open Label TIGeR-PaC Interim Analysis Shows Promising Data That Support Continued Clinical Investigation Of RenovoGemTM As A Treatment Option For Locally Advanced Pancreatic Cancer
Article By: Business Wire
Wednesday, March 8, 2023 8:23 AM EDT
Renovo RX today announced promising interim data in the Phase III open label TIGeR-PaC clinical trial.
In this article: RNXT
RenovoRX's Latest Innovative Technology Creates New Hope For Chemotherapy Patients
Article By: Shareholders Unite
Tuesday, February 28, 2023 11:15 PM EDT
RenovoRx takes existing chemotherapies and makes them more effective and less invasive, by being able to concentrate most of the chemotherapy agent on the tumor itself.
In this article: RNXT
NeurAxis: Should You Buy This IPO?
Article By: Avisol Capital Partners
Wednesday, February 8, 2023 12:14 PM EDT
As NeurAxis is ready to launch its IPO, we take a closer look to see if investors should be buying into the hype.
In this article: NRXS Also: MASI, BMY, PFE, ARNA, AMGN, GILD, ABBV, TAK
NeurAxis IPO Sets Stage To Take On Irritable Bowel Syndrome With A Non-Surgical Solution
Article By: Moon Kil Woong
Monday, February 6, 2023 4:14 PM EDT
As NeurAxis gears up for its upcoming IPO, we take a deep dive into the company to see if it's worth adding to your investment portfolio.
In this article: NRXS Also: ABBV, BMY, AMGN, ARNA, GILD, PFE, TAK
SurgePays Inc: A Strong Investment Opportunity In 2023
Video By: TalkMarkets TV
Monday, January 23, 2023 12:00 PM EDT
Get an inside look at why SurgePays Inc. is a strong investment opportunity for 2023 and why smallcap investors should consider adding SURG to their portfolio.
In this video: SURG
BriaCell Therapeutics' Mission: Destroy Breast Cancer
Article By: Lorimer Wilson
Wednesday, January 18, 2023 9:59 AM EDT
BriaCell would make a great buy and hold investment. If, and when, it brings a product directly to market, or is acquired by a major pharmaceutical company, its stock price should go up dramatically.
In this article: WWWW, BCTX, BCTXW Also: INCY
BriaCell Announces Positive End Of Phase II Meeting With The FDA For Bria-IMT(TM) Combination In Advanced Metastatic Breast Cancer
Article By: TalkMarkets Newswire
Wednesday, January 18, 2023 8:56 AM EDT
Registration study success could lead to a Biologics License Application (BLA) submission and commercialization approvals for BriaCell’s novel immunotherapy approach.
In this article: WWW, BCTX, BCTXW
SOBRSafe: A Disruptive Stock Worth The Risk
Article By: Kate Hayden
Wednesday, December 21, 2022 10:36 AM EDT
If something is cheap enough, and interesting enough, and has some concrete indications of holding higher prices - and you are clear-eyed about it - 'risk' is not intrinsically bad.
In this article: IGV, SOBR
1 to 16 of 760 Posts
1 2 3 ... 48